Bionomics’ Half-Year Report
23 févr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
15 févr. 2023 11h30 HE
|
Psycheceutical Bioscience, Inc.
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability,...
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
07 févr. 2023 10h31 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
06 févr. 2023 08h30 HE
|
Optimi Health Corp.
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under...
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
03 févr. 2023 00h01 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
02 févr. 2023 10h20 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
Quarterly Activities and Cashflow Report
30 janv. 2023 18h23 HE
|
Bionomics Ltd
ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
26 janv. 2023 12h15 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for...
Trimera Health Offers Medical Marijuana to Treat Patients With PTSD
05 janv. 2023 14h00 HE
|
Trimera Health
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Trimera Health is offering psychiatric treatment for post-traumatic stress disorder (PTSD) patients using marijuana, or cannabis, and building an uplifting...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19 déc. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...